×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Antiemetics Market Analysis

ID: MRFR/HC/6982-HCR
110 Pages
Rahul Gotadki
October 2025

Antiemetics Market Research Report By Drug Class (Serotonin 5-HT3 Receptor Antagonists, Dopamine Antagonists, Antihistamines, Cannabinoids, Neurokinin-1 Receptor Antagonists), By Route of Administration (Oral, Intravenous, Transdermal, Rectal, Subcutaneous), By Indication (Chemotherapy-Induced Nausea, Postoperative Nausea and Vomiting, Motion Sickness, Pregnancy-Related Nausea, Radiation-Induced Nausea), By End User (Hospitals, Clinics, Homecare Settings, Pharmacies) and By Regional (North America, Europe, South America, Asia-Pacific, Middle... read more

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Antiemetics Market Infographic
Purchase Options

Market Analysis

In-depth Analysis of Antiemetics Market Industry Landscape

The antiemetics market is an essential segment within the pharmaceutical enterprise, mostly focused on developing tablets to relieve nausea and vomiting signs. Market dynamics in this quarter are prompted by way of different factors, starting from technological improvements to changing healthcare regulations. Ongoing studies and development of sports play a pivotal role in shaping the market. Pharmaceutical organizations are investing in progressive formulations and drug delivery methods to beautify the efficacy of antiemetic tablets. This cognizance of innovation contributes appreciably to the market boom. Technological advancements in drug formula, inclusive of the development of long-appearing and sustained-launch formulations, are using market dynamics. These innovations now not only enhance patient compliance but also provide pharmaceutical organizations with a competitive edge. The increasing packages of antiemetics past conventional makes use of contribute to market boom. For example, the utilization of antiemetics in publish-operative settings and for coping with movement sickness broadens the market's scope and capacity purchaser base. The regulatory environment plays a crucial function in shaping market dynamics. Stringent rules and the need for approvals affect product improvement timelines and market entry strategies for pharmaceutical organizations working in the antiemetics region. Intense competition amongst pharmaceutical organizations drives innovation and influences pricing techniques. Companies strive to differentiate their merchandise through advanced efficacy, safety profiles, and affected person-friendly formulations to gain an aggressive advantage inside the market. The globalization of the pharmaceutical enterprise has opened new avenues for market growth. Companies are specializing in expanding their market presence across the world, thinking about factors including regional healthcare policies, market capability, and distribution channels. A growing emphasis on patient-centric healthcare has led to the development of antiemetic tablets that now not only effectively manipulate signs but additionally prioritize affected persons' comfort. This shift in attention affects product development and advertising strategies in the market. Collaborations and partnerships between pharmaceutical agencies and studies institutions are commonplace within the antiemetics market. These alliances foster expertise exchange, boost up studies efforts, and enhance the overall skills of enterprise gamers. Despite the fantastic dynamics, the market faces demanding situations, including patent expirations, universal competition, and capacity aspect consequences associated with antiemetic medicines. Overcoming these challenges requires strategic planning and non-stop funding for research and development. The destiny outlook for the antiemetics market remains positive, pushed with the aid of an aggregate of demographic traits, technological innovations, and developing attention to the significance of managing nausea and vomiting in numerous clinical situations. As the market continues to evolve, adaptability and keen expertise of rising tendencies may be important for sustained success in this dynamic pharmaceutical zone.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What is the current valuation of the Antiemetics Market as of 2024?

The Antiemetics Market was valued at 37.54 USD Billion in 2024.

What is the projected market valuation for the Antiemetics Market in 2035?

The market is projected to reach 59.27 USD Billion by 2035.

What is the expected CAGR for the Antiemetics Market during the forecast period 2025 - 2035?

The expected CAGR for the Antiemetics Market during 2025 - 2035 is 4.24%.

Which drug class segment is anticipated to have the highest valuation in 2035?

The Serotonin 5-HT3 Receptor Antagonists segment is expected to reach between 15.0 USD Billion by 2035.

How does the valuation of the Neurokinin-1 Receptor Antagonists segment compare between 2024 and 2035?

The Neurokinin-1 Receptor Antagonists segment increased from 7.54 USD Billion in 2024 to a projected 14.27 USD Billion in 2035.

What are the leading routes of administration for antiemetic drugs in 2035?

In 2035, the Subcutaneous route is projected to reach 18.27 USD Billion, making it a leading administration method.

Which end user segment is expected to dominate the Antiemetics Market by 2035?

Hospitals are anticipated to dominate the market, with a projected valuation of 23.12 USD Billion in 2035.

What indications are driving growth in the Antiemetics Market?

Chemotherapy-Induced Nausea is projected to be a key driver, with a valuation expected to reach 15.0 USD Billion by 2035.

Who are the key players in the Antiemetics Market?

Key players include Roche, Novartis, GlaxoSmithKline, and Merck & Co., among others.

What is the projected growth for the Antihistamines segment from 2024 to 2035?

The Antihistamines segment is expected to grow from 7.0 USD Billion in 2024 to 10.0 USD Billion by 2035.

Market Summary

As per MRFR analysis, the Antiemetics Market Size was estimated at 37.54 USD Billion in 2024. The Antiemetics industry is projected to grow from 39.13 USD Billion in 2025 to 59.27 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.24 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Antiemetics Market is experiencing robust growth driven by technological advancements and increasing demand for personalized medicine.

  • North America remains the largest market for antiemetics, driven by a well-established healthcare infrastructure.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and awareness.
  • Serotonin 5-HT3 receptor antagonists dominate the market, while dopamine antagonists are witnessing the fastest growth due to evolving treatment paradigms.
  • Key market drivers include the increasing incidence of nausea and vomiting disorders and the expansion of healthcare infrastructure, which enhance treatment accessibility.

Market Size & Forecast

2024 Market Size 37.54 (USD Billion)
2035 Market Size 59.27 (USD Billion)
CAGR (2025 - 2035) 4.24%
Largest Regional Market Share in 2024 North America

Major Players

<p>Roche (CH), Novartis (CH), GlaxoSmithKline (GB), Bristol-Myers Squibb (US), Merck & Co. (US), Teva Pharmaceutical Industries (IL), AstraZeneca (GB), Sanofi (FR), Eisai Co., Ltd. (JP)</p>

Market Trends

The Antiemetics Market is currently experiencing a dynamic evolution, driven by a confluence of factors that influence both demand and supply. The increasing prevalence of nausea and vomiting associated with various medical conditions, including chemotherapy, motion sickness, and postoperative recovery, has led to a heightened focus on effective antiemetic therapies. Furthermore, the growing awareness of the side effects associated with untreated nausea has prompted healthcare providers to prioritize the prescription of antiemetic medications. This shift in clinical practice underscores the importance of addressing patient comfort and quality of life, which appears to be a central theme in contemporary healthcare delivery. In addition to the rising demand for antiemetic treatments, the Antiemetics Market is also witnessing significant advancements in drug development. Pharmaceutical companies are investing in research to create novel formulations and delivery methods that enhance the efficacy and safety profiles of existing antiemetic agents. This trend suggests a potential for increased competition among manufacturers, as they strive to differentiate their products in a crowded marketplace. Moreover, the integration of technology in drug delivery systems may further revolutionize how antiemetics are administered, potentially improving patient adherence and outcomes. Overall, the Antiemetics Market is poised for continued growth, driven by both clinical needs and innovative solutions.

Rising Demand for Personalized Medicine

The Antiemetics Market is increasingly leaning towards personalized medicine approaches. Tailoring antiemetic therapies to individual patient profiles may enhance treatment efficacy and minimize adverse effects. This trend reflects a broader shift in healthcare towards customized treatment plans, which could lead to improved patient satisfaction and outcomes.

Technological Advancements in Drug Delivery

Innovations in drug delivery systems are transforming the Antiemetics Market. New technologies, such as transdermal patches and smart pills, are being developed to improve the administration of antiemetic medications. These advancements may enhance patient compliance and ensure more consistent therapeutic effects.

Growing Focus on Preventive Care

There is a noticeable shift towards preventive care within the Antiemetics Market. Healthcare providers are increasingly emphasizing the importance of preemptive antiemetic treatment, particularly in high-risk populations. This proactive approach aims to mitigate the onset of nausea and vomiting, thereby improving overall patient experiences.

Antiemetics Market Market Drivers

Growing Geriatric Population

The Antiemetics Market is significantly influenced by the growing geriatric population, which is more susceptible to conditions that cause nausea and vomiting. As the elderly population increases, so does the prevalence of chronic diseases and the use of multiple medications, which can lead to adverse effects such as nausea. This demographic shift is prompting healthcare providers to prioritize effective antiemetic treatments to improve the quality of life for older adults. Furthermore, the increasing number of elderly patients undergoing surgical procedures and chemotherapy is likely to drive demand for antiemetics. Consequently, pharmaceutical companies are focusing on developing formulations specifically tailored to meet the needs of this population, thereby expanding their market presence.

Advancements in Drug Development

The Antiemetics Market is witnessing advancements in drug development, which are likely to enhance treatment options for patients. Innovative research and development efforts are focusing on creating more effective antiemetic agents with fewer side effects. The introduction of novel compounds and biologics is expected to provide alternatives to traditional antiemetics, catering to diverse patient needs. Additionally, the integration of technology in drug development processes, such as artificial intelligence and machine learning, may streamline the discovery of new antiemetic therapies. This progress not only improves patient outcomes but also stimulates competition among pharmaceutical companies, potentially leading to a broader range of products in the antiemetics market.

Rising Awareness of Treatment Options

The Antiemetics Market benefits from the rising awareness of treatment options available for nausea and vomiting. Patients are becoming more informed about the various antiemetic medications and their efficacy, leading to increased demand. Educational campaigns by healthcare organizations and pharmaceutical companies play a crucial role in disseminating information about the importance of managing nausea effectively. This heightened awareness is likely to result in more patients seeking medical advice and treatment, thereby expanding the market. Furthermore, the introduction of new formulations and delivery methods, such as oral dissolving tablets and transdermal patches, may enhance patient compliance and satisfaction, contributing to market growth.

Expansion of Healthcare Infrastructure

The Antiemetics Market is poised for growth as healthcare infrastructure continues to expand in various regions. Enhanced access to healthcare services, particularly in developing countries, is likely to increase the diagnosis and treatment of conditions associated with nausea and vomiting. As hospitals and clinics improve their facilities and services, the availability of antiemetic medications is expected to rise. This expansion is supported by government initiatives aimed at improving healthcare access, which may lead to a higher demand for antiemetics. Additionally, the increasing number of outpatient procedures and surgeries contributes to the need for effective antiemetic solutions, further driving the market's growth.

Increasing Incidence of Nausea and Vomiting Disorders

The Antiemetics Market is experiencing growth due to the rising incidence of nausea and vomiting disorders, which are prevalent in various medical conditions. Conditions such as chemotherapy-induced nausea, postoperative nausea, and motion sickness contribute significantly to the demand for antiemetic medications. According to recent data, approximately 70% of cancer patients undergoing chemotherapy experience nausea, necessitating effective antiemetic treatments. This increasing patient population drives pharmaceutical companies to innovate and expand their product offerings in the antiemetics market. Furthermore, the growing awareness among healthcare professionals regarding the importance of managing these symptoms effectively is likely to bolster the market, as more patients seek relief from these debilitating conditions.

Market Segment Insights

By Drug Class: Serotonin 5-HT3 Receptor Antagonists (Largest) vs. Dopamine Antagonists (Fastest-Growing)

<p>The antiemetics market is characterized by a diverse range of drug classes, each contributing to the overall share in unique ways. Serotonin 5-HT3 receptor antagonists hold the largest segment share, primarily due to their established efficacy in managing nausea and vomiting associated with chemotherapy and postoperative situations. In contrast, dopamine antagonists are witnessing rapid growth, spurred by increasing awareness and prescriptions, as they offer alternative therapeutic options for patients experiencing nausea from various causes. Looking ahead, the antiemetics market is poised for transformation with emerging trends showcasing enhanced patient compliance and development of novel therapeutics. The demand for innovative formulations, including oral sprays and long-acting injectables, is anticipated to drive the growth of dopamine antagonists significantly. Additionally, expanding indications and better safety profiles are likely to propel the adoption of these treatments, influencing market dynamics positively.</p>

<p>Serotonin 5-HT3 Receptor Antagonists (Dominant) vs. Dopamine Antagonists (Emerging)</p>

<p>Serotonin 5-HT3 receptor antagonists have established themselves as a dominant force in the antiemetics market due to their proven efficacy and safety profile. They are widely utilized for prophylaxis and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and surgery. On the other hand, dopamine antagonists are gaining traction as an emerging alternative, offering versatile options for patients suffering from various forms of nausea and vomiting. These drugs are particularly appealing due to their broader neurologic targeting and improved side effect management, positioning them effectively in the competitive landscape. As treatment paradigms evolve, the distinct characteristics of each drug class will influence prescribing trends and market share in the antiemetics arena.</p>

By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

<p>In the Antiemetics Market, the route of administration is pivotal in determining treatment efficacy and patient compliance. The Oral segment holds the largest market share, as it is the most preferred method for patients due to its convenience and ease of use. Following Oral, the Intravenous route, while smaller in share, has been gaining traction among healthcare providers due to its rapid onset of action, particularly in acute settings.</p>

<p>Oral (Dominant) vs. Intravenous (Emerging)</p>

<p>The Oral route of administration is recognized as the dominant choice for antiemetic therapies, primarily due to its user-friendliness and high compliance rates among patients. It is widely utilized in outpatient settings where convenience is paramount. Conversely, the Intravenous route has emerged as a critical option, especially in hospitals for patients who require immediate relief from severe nausea and vomiting. Its ability to deliver medications directly into the bloodstream results in faster therapeutic effects, positioning it as an important alternative for acute care scenarios.</p>

By Indication: Chemotherapy-Induced Nausea (Largest) vs. Postoperative Nausea and Vomiting (Fastest-Growing)

<p>The Antiemetics Market is significantly influenced by various indications, with chemotherapy-induced nausea representing the largest segment due to the rising prevalence of cancer and cancer treatments worldwide. Following this, postoperative nausea and vomiting is gaining traction as a critical area of focus, especially with increasing surgical procedures and the need for effective management of nausea during recovery. Motion sickness, pregnancy-related nausea, and radiation-induced nausea also contribute to the market, although they hold smaller shares compared to the leading segments.</p>

<p>Chemotherapy-Induced Nausea (Dominant) vs. Postoperative Nausea and Vomiting (Emerging)</p>

<p>Chemotherapy-induced nausea is a dominant area in the Antiemetics Market, driven by the growing patient population undergoing cancer treatments and the subsequent need for nausea management. This segment benefits from established treatment protocols and a variety of effective antiemetic agents. Conversely, postoperative nausea and vomiting has emerged as a critical focus due to the increasing volume of surgical procedures and a heightened awareness of the impact of nausea on recovery times. Innovative therapies are being developed in this area, making it increasingly relevant as healthcare providers seek to enhance patient comfort and satisfaction during the postoperative phase.</p>

By End User: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

<p>In the Antiemetics Market, hospitals account for the largest share, primarily due to their role as the primary healthcare providers for patients undergoing complex treatments like chemotherapy or surgeries that often induce nausea and vomiting. Clinics and pharmacies also contribute significantly to the market, catering to outpatients and providing accessible remedies for motion sickness or post-operative needs. Homecare settings are gaining traction as they offer patient-friendly solutions for managing antiemetic therapies outside of institutional settings.</p>

<p>Homecare Settings (Fastest-Growing) vs. Clinics (Dominant)</p>

<p>Homecare settings are emerging as the fastest-growing segment within the Antiemetics Market, driven by the increasing patient preference for receiving treatment in the comfort of their homes. This shift is supported by advancements in telemedicine and portable antiemetic solutions that allow for easy administration. On the other hand, clinics hold a dominant position due to their direct access to patients in need of antiemetic therapies for various conditions. They provide immediate care and prescription services, which complements the hospital and homecare segments, creating a well-rounded approach to antiemetic treatment.</p>

Get more detailed insights about Antiemetics Market Research Report - Global Forecast till 2035

Regional Insights

The Antiemetics Market is projected to reach a valuation of 36.01 USD Billion in 2023, with a significant focus on regional insights that illustrate varying demand and market dynamics. In North America, the market is valued at 15.0 USD Billion, highlighting its majority holding and dominance in the sector, primarily driven by high healthcare expenditure and a growing prevalence of nausea-related disorders.

Europe follows closely with a valuation of 10.5 USD Billion, reflecting its significant yet smaller role, attributed to advanced healthcare systems and increasing use of antiemetic medications.The APAC region shows a valuation of 7.5 USD Billion in 2023, indicating robust growth potential owing to rising healthcare access and awareness. Meanwhile, South America and MEA represent smaller segments, valued at 1.2 USD Billion and 2.81 USD Billion, respectively, showcasing opportunities for market expansion but currently less dominance.

The Antiemetics Market statistics reveal a complex landscape where North America and Europe remain critical players, and emerging markets in APAC are increasingly gaining traction, influenced by factors such as evolving healthcare policies, demographic changes, and rising living standards.

Antiemetics Market Regional Insights

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The competitive insights of the Antiemetics Market reveal a dynamic landscape characterized by significant advancements in pharmaceutical developments and the growing demand for effective antiemetic treatments. As healthcare providers increasingly prioritize patient comfort and quality of life, the need for innovative solutions to manage nausea and vomiting, particularly associated with chemotherapy, radiation therapy, and postoperative recovery, has become paramount. Companies within this sector are focusing on research and development to introduce novel compounds and enhance the efficacy of existing formulations.

This drive for innovation, coupled with strategic partnerships and mergers, creates a robust competitive environment where companies seek to establish market share while addressing the evolving needs of healthcare practitioners and patients alike.Sanofi stands as a prominent player in the Antiemetics Market, leveraging its strong portfolio of pharmaceutical products that cater to various medical conditions, including nausea and vomiting. The company possesses a reputation for its commitment to research and development, which has allowed it to introduce diverse antiemetic solutions aimed at different patient demographics and treatment settings.

Sanofi's strong market presence is bolstered by its extensive distribution channels and a well-established global network, enabling it to reach various regions effectively. The firm's innovative approach to drug formulation and its focus on patient-centered solutions contribute to its strengths, alongside its ability to address unmet medical needs with efficacy and safety as paramount considerations.GSK has carved a notable niche in the Antiemetics Market, capitalizing on its extensive expertise in innovation and dedicated research.

The company is recognized for its strategic direction in developing antiemetic therapies that address both acute and chronic situations experienced by patients, particularly in oncology and postoperative care. GSK's strong emphasis on partnerships with healthcare professionals and institutions aids in reinforcing its market presence, allowing it to tailor its products according to the specific needs of healthcare settings. The company's commitment to leveraging cutting-edge technology in drug development ensures that its antiemetic offerings remain competitive and effective, addressing both current clinical challenges and future demands within the healthcare landscape.

GSK's proactive approach to engaging with patient communities adds to its strengths, enhancing both its brand loyalty and reputation in delivering quality therapeutic options.

Key Companies in the Antiemetics Market market include

Industry Developments

The Antiemetics Market is witnessing significant developments, with companies like Sanofi, GSK, AbbVie, and Pfizer actively addressing the growing demand for innovative therapies. The market is shifting towards advanced formulations and novel drug delivery systems that enhance patient compliance and efficacy. Recent entries of new products and enhancements in existing medications have underscored the commitment of these firms to combat nausea and vomiting from diverse causes such as chemotherapy and postoperative pain. Additionally, Eisai and Merck have been recognized for their efforts in research and development, focusing on creating more effective antiemetic agents.

Recent merger and acquisition activity, primarily involving Bayer and Amgen, highlights strategic moves to expand product portfolios and market presence. The growth in market valuation is notable, driven by an increasing prevalence of conditions requiring antiemetic therapies, influencing the overall landscape, while companies like Johnson & Johnson and Roche are expanding their research endeavors to identify next-generation solutions. This dynamic environment showcases the urgent need for continuous innovation and strategic partnerships among the major players in the antiemetics sector.

Future Outlook

Antiemetics Market Future Outlook

<p>The Antiemetics Market is projected to grow at a 4.24% CAGR from 2024 to 2035, driven by increasing demand for effective nausea management and advancements in drug formulations.</p>

New opportunities lie in:

  • <p>Development of personalized antiemetic therapies for specific patient demographics.</p>
  • <p>Expansion of telehealth services for remote antiemetic consultations.</p>
  • <p>Investment in biodegradable drug delivery systems for enhanced patient compliance.</p>

<p>By 2035, the Antiemetics Market is expected to achieve substantial growth, reflecting evolving healthcare needs.</p>

Market Segmentation

Antiemetics Market End User Outlook

  • Hospitals
  • Clinics
  • Homecare Settings
  • Pharmacies

Antiemetics Market Drug Class Outlook

  • Serotonin 5-HT3 Receptor Antagonists
  • Dopamine Antagonists
  • Antihistamines
  • Cannabinoids
  • Neurokinin-1 Receptor Antagonists

Antiemetics Market Indication Outlook

  • Chemotherapy-Induced Nausea
  • Postoperative Nausea and Vomiting
  • Motion Sickness
  • Pregnancy-Related Nausea
  • Radiation-Induced Nausea

Antiemetics Market Route of Administration Outlook

  • Oral
  • Intravenous
  • Transdermal
  • Rectal
  • Subcutaneous

Report Scope

MARKET SIZE 202437.54(USD Billion)
MARKET SIZE 202539.13(USD Billion)
MARKET SIZE 203559.27(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)4.24% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesAdvancements in personalized medicine enhance treatment efficacy in the Antiemetics Market.
Key Market DynamicsRising demand for innovative antiemetic therapies drives competition and influences regulatory frameworks in the market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Antiemetics Market as of 2024?

The Antiemetics Market was valued at 37.54 USD Billion in 2024.

What is the projected market valuation for the Antiemetics Market in 2035?

The market is projected to reach 59.27 USD Billion by 2035.

What is the expected CAGR for the Antiemetics Market during the forecast period 2025 - 2035?

The expected CAGR for the Antiemetics Market during 2025 - 2035 is 4.24%.

Which drug class segment is anticipated to have the highest valuation in 2035?

The Serotonin 5-HT3 Receptor Antagonists segment is expected to reach between 15.0 USD Billion by 2035.

How does the valuation of the Neurokinin-1 Receptor Antagonists segment compare between 2024 and 2035?

The Neurokinin-1 Receptor Antagonists segment increased from 7.54 USD Billion in 2024 to a projected 14.27 USD Billion in 2035.

What are the leading routes of administration for antiemetic drugs in 2035?

In 2035, the Subcutaneous route is projected to reach 18.27 USD Billion, making it a leading administration method.

Which end user segment is expected to dominate the Antiemetics Market by 2035?

Hospitals are anticipated to dominate the market, with a projected valuation of 23.12 USD Billion in 2035.

What indications are driving growth in the Antiemetics Market?

Chemotherapy-Induced Nausea is projected to be a key driver, with a valuation expected to reach 15.0 USD Billion by 2035.

Who are the key players in the Antiemetics Market?

Key players include Roche, Novartis, GlaxoSmithKline, and Merck & Co., among others.

What is the projected growth for the Antihistamines segment from 2024 to 2035?

The Antihistamines segment is expected to grow from 7.0 USD Billion in 2024 to 10.0 USD Billion by 2035.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    2. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    2. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. Healthcare, BY Drug Class (USD Billion)
      1. Serotonin 5-HT3 Receptor Antagonists
      2. Dopamine Antagonists
      3. Antihistamines
      4. Cannabinoids
      5. Neurokinin-1 Receptor Antagonists
    2. Healthcare, BY Route of Administration (USD Billion)
      1. Oral
      2. Intravenous
      3. Transdermal
      4. Rectal
      5. Subcutaneous
    3. Healthcare, BY Indication (USD Billion)
      1. Chemotherapy-Induced Nausea
      2. Postoperative Nausea and Vomiting
      3. Motion Sickness
      4. Pregnancy-Related Nausea
      5. Radiation-Induced Nausea
    4. Healthcare, BY End User (USD Billion)
      1. Hospitals
      2. Clinics
      3. Homecare Settings
      4. Pharmacies
    5. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    2. Company Profiles
      1. Roche (CH)
      2. Novartis (CH)
      3. GlaxoSmithKline (GB)
      4. Bristol-Myers Squibb (US)
      5. Merck & Co. (US)
      6. Teva Pharmaceutical Industries (IL)
      7. AstraZeneca (GB)
      8. Sanofi (FR)
      9. Eisai Co., Ltd. (JP)
    3. Appendix
      1. References
      2. Related Reports
  6. LIST OF FIGURES
    1. MARKET SYNOPSIS
    2. NORTH AMERICA MARKET ANALYSIS
    3. US MARKET ANALYSIS BY DRUG CLASS
    4. US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. US MARKET ANALYSIS BY INDICATION
    6. US MARKET ANALYSIS BY END USER
    7. CANADA MARKET ANALYSIS BY DRUG CLASS
    8. CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    9. CANADA MARKET ANALYSIS BY INDICATION
    10. CANADA MARKET ANALYSIS BY END USER
    11. EUROPE MARKET ANALYSIS
    12. GERMANY MARKET ANALYSIS BY DRUG CLASS
    13. GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    14. GERMANY MARKET ANALYSIS BY INDICATION
    15. GERMANY MARKET ANALYSIS BY END USER
    16. UK MARKET ANALYSIS BY DRUG CLASS
    17. UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    18. UK MARKET ANALYSIS BY INDICATION
    19. UK MARKET ANALYSIS BY END USER
    20. FRANCE MARKET ANALYSIS BY DRUG CLASS
    21. FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    22. FRANCE MARKET ANALYSIS BY INDICATION
    23. FRANCE MARKET ANALYSIS BY END USER
    24. RUSSIA MARKET ANALYSIS BY DRUG CLASS
    25. RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    26. RUSSIA MARKET ANALYSIS BY INDICATION
    27. RUSSIA MARKET ANALYSIS BY END USER
    28. ITALY MARKET ANALYSIS BY DRUG CLASS
    29. ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    30. ITALY MARKET ANALYSIS BY INDICATION
    31. ITALY MARKET ANALYSIS BY END USER
    32. SPAIN MARKET ANALYSIS BY DRUG CLASS
    33. SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    34. SPAIN MARKET ANALYSIS BY INDICATION
    35. SPAIN MARKET ANALYSIS BY END USER
    36. REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
    37. REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    38. REST OF EUROPE MARKET ANALYSIS BY INDICATION
    39. REST OF EUROPE MARKET ANALYSIS BY END USER
    40. APAC MARKET ANALYSIS
    41. CHINA MARKET ANALYSIS BY DRUG CLASS
    42. CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    43. CHINA MARKET ANALYSIS BY INDICATION
    44. CHINA MARKET ANALYSIS BY END USER
    45. INDIA MARKET ANALYSIS BY DRUG CLASS
    46. INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    47. INDIA MARKET ANALYSIS BY INDICATION
    48. INDIA MARKET ANALYSIS BY END USER
    49. JAPAN MARKET ANALYSIS BY DRUG CLASS
    50. JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    51. JAPAN MARKET ANALYSIS BY INDICATION
    52. JAPAN MARKET ANALYSIS BY END USER
    53. SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
    54. SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    55. SOUTH KOREA MARKET ANALYSIS BY INDICATION
    56. SOUTH KOREA MARKET ANALYSIS BY END USER
    57. MALAYSIA MARKET ANALYSIS BY DRUG CLASS
    58. MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    59. MALAYSIA MARKET ANALYSIS BY INDICATION
    60. MALAYSIA MARKET ANALYSIS BY END USER
    61. THAILAND MARKET ANALYSIS BY DRUG CLASS
    62. THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    63. THAILAND MARKET ANALYSIS BY INDICATION
    64. THAILAND MARKET ANALYSIS BY END USER
    65. INDONESIA MARKET ANALYSIS BY DRUG CLASS
    66. INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    67. INDONESIA MARKET ANALYSIS BY INDICATION
    68. INDONESIA MARKET ANALYSIS BY END USER
    69. REST OF APAC MARKET ANALYSIS BY DRUG CLASS
    70. REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    71. REST OF APAC MARKET ANALYSIS BY INDICATION
    72. REST OF APAC MARKET ANALYSIS BY END USER
    73. SOUTH AMERICA MARKET ANALYSIS
    74. BRAZIL MARKET ANALYSIS BY DRUG CLASS
    75. BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    76. BRAZIL MARKET ANALYSIS BY INDICATION
    77. BRAZIL MARKET ANALYSIS BY END USER
    78. MEXICO MARKET ANALYSIS BY DRUG CLASS
    79. MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    80. MEXICO MARKET ANALYSIS BY INDICATION
    81. MEXICO MARKET ANALYSIS BY END USER
    82. ARGENTINA MARKET ANALYSIS BY DRUG CLASS
    83. ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    84. ARGENTINA MARKET ANALYSIS BY INDICATION
    85. ARGENTINA MARKET ANALYSIS BY END USER
    86. REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
    87. REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    88. REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    89. REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    90. MEA MARKET ANALYSIS
    91. GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
    92. GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    93. GCC COUNTRIES MARKET ANALYSIS BY INDICATION
    94. GCC COUNTRIES MARKET ANALYSIS BY END USER
    95. SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
    96. SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    97. SOUTH AFRICA MARKET ANALYSIS BY INDICATION
    98. SOUTH AFRICA MARKET ANALYSIS BY END USER
    99. REST OF MEA MARKET ANALYSIS BY DRUG CLASS
    100. REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    101. REST OF MEA MARKET ANALYSIS BY INDICATION
    102. REST OF MEA MARKET ANALYSIS BY END USER
    103. KEY BUYING CRITERIA OF HEALTHCARE
    104. RESEARCH PROCESS OF MRFR
    105. DRO ANALYSIS OF HEALTHCARE
    106. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. SUPPLY / VALUE CHAIN: HEALTHCARE
    109. HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
    110. HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
    111. HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    112. HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    113. HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    114. HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
    115. HEALTHCARE, BY END USER, 2024 (% SHARE)
    116. HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    117. BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. LIST OF ASSUMPTIONS
    2. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    3. US MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    4. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    5. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    6. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    7. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    8. France MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    9. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    10. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    11. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    12. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    13. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    14. China MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    15. India MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    16. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    17. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    18. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    19. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    20. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    21. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    22. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    23. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    24. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    25. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    26. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    27. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    28. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    29. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    30. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DRUG CLASS, 2025-2035 (USD Billion)
      2. BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY END USER, 2025-2035 (USD Billion)
    31. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    32. ACQUISITION/PARTNERSHIP

Antiemetics Market Segmentation

  • Antiemetics Market By Drug Class (USD Billion, 2019-2032)
    • Serotonin 5-HT3 Receptor Antagonists
    • Dopamine Antagonists
    • Antihistamines
    • Cannabinoids
    • Neurokinin-1 Receptor Antagonists

 

  • Antiemetics Market By Route of Administration (USD Billion, 2019-2032)
    • Oral
    • Intravenous
    • Transdermal
    • Rectal
    • Subcutaneous

 

  • Antiemetics Market By Indication (USD Billion, 2019-2032)
    • Chemotherapy-Induced Nausea
    • Postoperative Nausea and Vomiting
    • Motion Sickness
    • Pregnancy-Related Nausea
    • Radiation-Induced Nausea

 

  • Antiemetics Market By End User (USD Billion, 2019-2032)
    • Hospitals
    • Clinics
    • Homecare Settings
    • Pharmacies

 

  • Antiemetics Market By Regional (USD Billion, 2019-2032)
    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

 

Antiemetics Market Regional Outlook (USD Billion, 2019-2032)

 

 

  • North America Outlook (USD Billion, 2019-2032)
    • North America Antiemetics Market by Drug Class Type
      • Serotonin 5-HT3 Receptor Antagonists
      • Dopamine Antagonists
      • Antihistamines
      • Cannabinoids
      • Neurokinin-1 Receptor Antagonists
    • North America Antiemetics Market by Route of Administration Type
      • Oral
      • Intravenous
      • Transdermal
      • Rectal
      • Subcutaneous
    • North America Antiemetics Market by Indication Type
      • Chemotherapy-Induced Nausea
      • Postoperative Nausea and Vomiting
      • Motion Sickness
      • Pregnancy-Related Nausea
      • Radiation-Induced Nausea
    • North America Antiemetics Market by End User Type
      • Hospitals
      • Clinics
      • Homecare Settings
      • Pharmacies
    • North America Antiemetics Market by Regional Type
      • US
      • Canada
    • US Outlook (USD Billion, 2019-2032)
    • US Antiemetics Market by Drug Class Type
      • Serotonin 5-HT3 Receptor Antagonists
      • Dopamine Antagonists
      • Antihistamines
      • Cannabinoids
      • Neurokinin-1 Receptor Antagonists
    • US Antiemetics Market by Route of Administration Type
      • Oral
      • Intravenous
      • Transdermal
      • Rectal
      • Subcutaneous
    • US Antiemetics Market by Indication Type
      • Chemotherapy-Induced Nausea
      • Postoperative Nausea and Vomiting
      • Motion Sickness
      • Pregnancy-Related Nausea
      • Radiation-Induced Nausea
    • US Antiemetics Market by End User Type
      • Hospitals
      • Clinics
      • Homecare Settings
      • Pharmacies
    • CANADA Outlook (USD Billion, 2019-2032)
    • CANADA Antiemetics Market by Drug Class Type
      • Serotonin 5-HT3 Receptor Antagonists
      • Dopamine Antagonists
      • Antihistamines
      • Cannabinoids
      • Neurokinin-1 Receptor Antagonists
    • CANADA Antiemetics Market by Route of Administration Type
      • Oral
      • Intravenous
      • Transdermal
      • Rectal
      • Subcutaneous
    • CANADA Antiemetics Market by Indication Type
      • Chemotherapy-Induced Nausea
      • Postoperative Nausea and Vomiting
      • Motion Sickness
      • Pregnancy-Related Nausea
      • Radiation-Induced Nausea
    • CANADA Antiemetics Market by End User Type
      • Hospitals
      • Clinics
      • Homecare Settings
      • Pharmacies
    • Europe Outlook (USD Billion, 2019-2032)
      • Europe Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • Europe Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • Europe Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • Europe Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • Europe Antiemetics Market by Regional Type
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Spain
        • Rest of Europe
      • GERMANY Outlook (USD Billion, 2019-2032)
      • GERMANY Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • GERMANY Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • GERMANY Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • GERMANY Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • UK Outlook (USD Billion, 2019-2032)
      • UK Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • UK Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • UK Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • UK Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • FRANCE Outlook (USD Billion, 2019-2032)
      • FRANCE Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • FRANCE Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • FRANCE Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • FRANCE Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • RUSSIA Outlook (USD Billion, 2019-2032)
      • RUSSIA Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • RUSSIA Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • RUSSIA Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • RUSSIA Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • ITALY Outlook (USD Billion, 2019-2032)
      • ITALY Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • ITALY Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • ITALY Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • ITALY Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • SPAIN Outlook (USD Billion, 2019-2032)
      • SPAIN Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • SPAIN Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • SPAIN Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • SPAIN Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • REST OF EUROPE Outlook (USD Billion, 2019-2032)
      • REST OF EUROPE Antiemetics Market by Drug Class Type
        • Serotonin 5-HT3 Receptor Antagonists
        • Dopamine Antagonists
        • Antihistamines
        • Cannabinoids
        • Neurokinin-1 Receptor Antagonists
      • REST OF EUROPE Antiemetics Market by Route of Administration Type
        • Oral
        • Intravenous
        • Transdermal
        • Rectal
        • Subcutaneous
      • REST OF EUROPE Antiemetics Market by Indication Type
        • Chemotherapy-Induced Nausea
        • Postoperative Nausea and Vomiting
        • Motion Sickness
        • Pregnancy-Related Nausea
        • Radiation-Induced Nausea
      • REST OF EUROPE Antiemetics Market by End User Type
        • Hospitals
        • Clinics
        • Homecare Settings
        • Pharmacies
      • APAC Outlook (USD Billion, 2019-2032)
        • APAC Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • APAC Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • APAC Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • APAC Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • APAC Antiemetics Market by Regional Type
          • China
          • India
          • Japan
          • South Korea
          • Malaysia
          • Thailand
          • Indonesia
          • Rest of APAC
        • CHINA Outlook (USD Billion, 2019-2032)
        • CHINA Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • CHINA Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • CHINA Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • CHINA Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • INDIA Outlook (USD Billion, 2019-2032)
        • INDIA Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • INDIA Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • INDIA Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • INDIA Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • JAPAN Outlook (USD Billion, 2019-2032)
        • JAPAN Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • JAPAN Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • JAPAN Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • JAPAN Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • SOUTH KOREA Outlook (USD Billion, 2019-2032)
        • SOUTH KOREA Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • SOUTH KOREA Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • SOUTH KOREA Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • SOUTH KOREA Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • MALAYSIA Outlook (USD Billion, 2019-2032)
        • MALAYSIA Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • MALAYSIA Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • MALAYSIA Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • MALAYSIA Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • THAILAND Outlook (USD Billion, 2019-2032)
        • THAILAND Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • THAILAND Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • THAILAND Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • THAILAND Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • INDONESIA Outlook (USD Billion, 2019-2032)
        • INDONESIA Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • INDONESIA Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • INDONESIA Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • INDONESIA Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • REST OF APAC Outlook (USD Billion, 2019-2032)
        • REST OF APAC Antiemetics Market by Drug Class Type
          • Serotonin 5-HT3 Receptor Antagonists
          • Dopamine Antagonists
          • Antihistamines
          • Cannabinoids
          • Neurokinin-1 Receptor Antagonists
        • REST OF APAC Antiemetics Market by Route of Administration Type
          • Oral
          • Intravenous
          • Transdermal
          • Rectal
          • Subcutaneous
        • REST OF APAC Antiemetics Market by Indication Type
          • Chemotherapy-Induced Nausea
          • Postoperative Nausea and Vomiting
          • Motion Sickness
          • Pregnancy-Related Nausea
          • Radiation-Induced Nausea
        • REST OF APAC Antiemetics Market by End User Type
          • Hospitals
          • Clinics
          • Homecare Settings
          • Pharmacies
        • South America Outlook (USD Billion, 2019-2032)
          • South America Antiemetics Market by Drug Class Type
            • Serotonin 5-HT3 Receptor Antagonists
            • Dopamine Antagonists
            • Antihistamines
            • Cannabinoids
            • Neurokinin-1 Receptor Antagonists
          • South America Antiemetics Market by Route of Administration Type
            • Oral
            • Intravenous
            • Transdermal
            • Rectal
            • Subcutaneous
          • South America Antiemetics Market by Indication Type
            • Chemotherapy-Induced Nausea
            • Postoperative Nausea and Vomiting
            • Motion Sickness
            • Pregnancy-Related Nausea
            • Radiation-Induced Nausea
          • South America Antiemetics Market by End User Type
            • Hospitals
            • Clinics
            • Homecare Settings
            • Pharmacies
          • South America Antiemetics Market by Regional Type
            • Brazil
            • Mexico
            • Argentina
            • Rest of South America
          • BRAZIL Outlook (USD Billion, 2019-2032)
          • BRAZIL Antiemetics Market by Drug Class Type
            • Serotonin 5-HT3 Receptor Antagonists
            • Dopamine Antagonists
            • Antihistamines
            • Cannabinoids
            • Neurokinin-1 Receptor Antagonists
          • BRAZIL Antiemetics Market by Route of Administration Type
            • Oral
            • Intravenous
            • Transdermal
            • Rectal
            • Subcutaneous
          • BRAZIL Antiemetics Market by Indication Type
            • Chemotherapy-Induced Nausea
            • Postoperative Nausea and Vomiting
            • Motion Sickness
            • Pregnancy-Related Nausea
            • Radiation-Induced Nausea
          • BRAZIL Antiemetics Market by End User Type
            • Hospitals
            • Clinics
            • Homecare Settings
            • Pharmacies
          • MEXICO Outlook (USD Billion, 2019-2032)
          • MEXICO Antiemetics Market by Drug Class Type
            • Serotonin 5-HT3 Receptor Antagonists
            • Dopamine Antagonists
            • Antihistamines
            • Cannabinoids
            • Neurokinin-1 Receptor Antagonists
          • MEXICO Antiemetics Market by Route of Administration Type
            • Oral
            • Intravenous
            • Transdermal
            • Rectal
            • Subcutaneous
          • MEXICO Antiemetics Market by Indication Type
            • Chemotherapy-Induced Nausea
            • Postoperative Nausea and Vomiting
            • Motion Sickness
            • Pregnancy-Related Nausea
            • Radiation-Induced Nausea
          • MEXICO Antiemetics Market by End User Type
            • Hospitals
            • Clinics
            • Homecare Settings
            • Pharmacies
          • ARGENTINA Outlook (USD Billion, 2019-2032)
          • ARGENTINA Antiemetics Market by Drug Class Type
            • Serotonin 5-HT3 Receptor Antagonists
            • Dopamine Antagonists
            • Antihistamines
            • Cannabinoids
            • Neurokinin-1 Receptor Antagonists
          • ARGENTINA Antiemetics Market by Route of Administration Type
            • Oral
            • Intravenous
            • Transdermal
            • Rectal
            • Subcutaneous
          • ARGENTINA Antiemetics Market by Indication Type
            • Chemotherapy-Induced Nausea
            • Postoperative Nausea and Vomiting
            • Motion Sickness
            • Pregnancy-Related Nausea
            • Radiation-Induced Nausea
          • ARGENTINA Antiemetics Market by End User Type
            • Hospitals
            • Clinics
            • Homecare Settings
            • Pharmacies
          • REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2032)
          • REST OF SOUTH AMERICA Antiemetics Market by Drug Class Type
            • Serotonin 5-HT3 Receptor Antagonists
            • Dopamine Antagonists
            • Antihistamines
            • Cannabinoids
            • Neurokinin-1 Receptor Antagonists
          • REST OF SOUTH AMERICA Antiemetics Market by Route of Administration Type
            • Oral
            • Intravenous
            • Transdermal
            • Rectal
            • Subcutaneous
          • REST OF SOUTH AMERICA Antiemetics Market by Indication Type
            • Chemotherapy-Induced Nausea
            • Postoperative Nausea and Vomiting
            • Motion Sickness
            • Pregnancy-Related Nausea
            • Radiation-Induced Nausea
          • REST OF SOUTH AMERICA Antiemetics Market by End User Type
            • Hospitals
            • Clinics
            • Homecare Settings
            • Pharmacies
          • MEA Outlook (USD Billion, 2019-2032)
            • MEA Antiemetics Market by Drug Class Type
              • Serotonin 5-HT3 Receptor Antagonists
              • Dopamine Antagonists
              • Antihistamines
              • Cannabinoids
              • Neurokinin-1 Receptor Antagonists
            • MEA Antiemetics Market by Route of Administration Type
              • Oral
              • Intravenous
              • Transdermal
              • Rectal
              • Subcutaneous
            • MEA Antiemetics Market by Indication Type
              • Chemotherapy-Induced Nausea
              • Postoperative Nausea and Vomiting
              • Motion Sickness
              • Pregnancy-Related Nausea
              • Radiation-Induced Nausea
            • MEA Antiemetics Market by End User Type
              • Hospitals
              • Clinics
              • Homecare Settings
              • Pharmacies
            • MEA Antiemetics Market by Regional Type
              • GCC Countries
              • South Africa
              • Rest of MEA
            • GCC COUNTRIES Outlook (USD Billion, 2019-2032)
            • GCC COUNTRIES Antiemetics Market by Drug Class Type
              • Serotonin 5-HT3 Receptor Antagonists
              • Dopamine Antagonists
              • Antihistamines
              • Cannabinoids
              • Neurokinin-1 Receptor Antagonists
            • GCC COUNTRIES Antiemetics Market by Route of Administration Type
              • Oral
              • Intravenous
              • Transdermal
              • Rectal
              • Subcutaneous
            • GCC COUNTRIES Antiemetics Market by Indication Type
              • Chemotherapy-Induced Nausea
              • Postoperative Nausea and Vomiting
              • Motion Sickness
              • Pregnancy-Related Nausea
              • Radiation-Induced Nausea
            • GCC COUNTRIES Antiemetics Market by End User Type
              • Hospitals
              • Clinics
              • Homecare Settings
              • Pharmacies
            • SOUTH AFRICA Outlook (USD Billion, 2019-2032)
            • SOUTH AFRICA Antiemetics Market by Drug Class Type
              • Serotonin 5-HT3 Receptor Antagonists
              • Dopamine Antagonists
              • Antihistamines
              • Cannabinoids
              • Neurokinin-1 Receptor Antagonists
            • SOUTH AFRICA Antiemetics Market by Route of Administration Type
              • Oral
              • Intravenous
              • Transdermal
              • Rectal
              • Subcutaneous
            • SOUTH AFRICA Antiemetics Market by Indication Type
              • Chemotherapy-Induced Nausea
              • Postoperative Nausea and Vomiting
              • Motion Sickness
              • Pregnancy-Related Nausea
              • Radiation-Induced Nausea
            • SOUTH AFRICA Antiemetics Market by End User Type
              • Hospitals
              • Clinics
              • Homecare Settings
              • Pharmacies
            • REST OF MEA Outlook (USD Billion, 2019-2032)
            • REST OF MEA Antiemetics Market by Drug Class Type
              • Serotonin 5-HT3 Receptor Antagonists
              • Dopamine Antagonists
              • Antihistamines
              • Cannabinoids
              • Neurokinin-1 Receptor Antagonists
            • REST OF MEA Antiemetics Market by Route of Administration Type
              • Oral
              • Intravenous
              • Transdermal
              • Rectal
              • Subcutaneous
            • REST OF MEA Antiemetics Market by Indication Type
              • Chemotherapy-Induced Nausea
              • Postoperative Nausea and Vomiting
              • Motion Sickness
              • Pregnancy-Related Nausea
              • Radiation-Induced Nausea
            • REST OF MEA Antiemetics Market by End User Type
              • Hospitals
              • Clinics
              • Homecare Settings
              • Pharmacies
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions